Biofrontera Stock Analysis
| BFRI Stock | USD 0.98 0.02 2.00% |
Biofrontera's financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Biofrontera's financial risk is the risk to Biofrontera stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that Biofrontera's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Biofrontera is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Biofrontera to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Biofrontera is said to be less leveraged. If creditors hold a majority of Biofrontera's assets, the Company is said to be highly leveraged.
Biofrontera is overvalued with Real Value of 0.77 and Hype Value of 0.98. The main objective of Biofrontera stock analysis is to determine its intrinsic value, which is an estimate of what Biofrontera is worth, separate from its market price. There are two main types of Biofrontera's stock analysis: fundamental analysis and technical analysis.
The Biofrontera stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Biofrontera's ongoing operational relationships across important fundamental and technical indicators.
Biofrontera | Build AI portfolio with Biofrontera Stock |
Biofrontera Stock Analysis Notes
About 12.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.65. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biofrontera recorded a loss per share of 1.5. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 5th of July 2023. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Biofrontera operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 69 people. For more info on Biofrontera please contact Erica CPA at 781 245 1325 or go to https://www.biofrontera-us.com.Biofrontera Investment Alerts
| Biofrontera had very high historical volatility over the last 90 days | |
| Biofrontera has some characteristics of a very speculative penny stock | |
| Biofrontera has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 37.3 M. Net Loss for the year was (17.76 M) with profit before overhead, payroll, taxes, and interest of 23.94 M. | |
| Biofrontera currently holds about 31.91 M in cash with (10.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 12.0% of the company shares are held by company insiders |
Biofrontera Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.63 M.Biofrontera Profitablity
The company has Profit Margin (PM) of (0.47) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.9) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.9.Technical Drivers
As of the 27th of January, Biofrontera shows the Risk Adjusted Performance of 0.0172, mean deviation of 3.66, and Downside Deviation of 6.29. Biofrontera technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Biofrontera Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Moving Average is predictive technique used to analyze Biofrontera price data points by creating a series of averages of different subsets of Biofrontera entire price series.
Biofrontera Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biofrontera insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biofrontera's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biofrontera insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vv Beteiligungen Aktiengesellschaft over two months ago Insider Trading | ||
Link Christian Alexander Ansgar over three months ago Insider Trading | ||
Leffler Eugene Frederick over three months ago Disposition of 87500 shares by Leffler Eugene Frederick of Biofrontera subject to Rule 16b-3 | ||
Hermann Luebbert over six months ago Acquisition by Hermann Luebbert of 113379 shares of Biofrontera at 4.77 subject to Rule 16b-3 | ||
Borer John J Iii over a year ago Acquisition by Borer John J Iii of 22000 shares of Biofrontera subject to Rule 16b-3 | ||
Hermann Luebbert over a year ago Acquisition by Hermann Luebbert of 190840 shares of Biofrontera subject to Rule 16b-3 | ||
Hermann Luebbert over a year ago Disposition of 4771 shares by Hermann Luebbert of Biofrontera subject to Rule 16b-3 | ||
Wedge Loretta M. over a year ago Insider Trading | ||
Luebbert Hermann over a year ago Exercise or conversion by Luebbert Hermann of 95420 shares of Biofrontera subject to Rule 16b-3 |
Biofrontera Outstanding Bonds
Biofrontera issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biofrontera uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biofrontera bonds can be classified according to their maturity, which is the date when Biofrontera has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Biofrontera Predictive Daily Indicators
Biofrontera intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biofrontera stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Biofrontera Forecast Models
Biofrontera's time-series forecasting models are one of many Biofrontera's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biofrontera's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Biofrontera Debt to Cash Allocation
As Biofrontera follows its natural business cycle, the capital allocation decisions will not magically go away. Biofrontera's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Biofrontera currently holds 4.92 M in liabilities. Biofrontera has a current ratio of 3.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Biofrontera's use of debt, we should always consider it together with its cash and equity.Biofrontera Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Biofrontera's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Biofrontera, which in turn will lower the firm's financial flexibility.Biofrontera Corporate Bonds Issued
Most Biofrontera bonds can be classified according to their maturity, which is the date when Biofrontera has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Biofrontera Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Biofrontera prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biofrontera shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Biofrontera. By using and applying Biofrontera Stock analysis, traders can create a robust methodology for identifying Biofrontera entry and exit points for their positions.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Biofrontera operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Biofrontera to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Complementary Tools for Biofrontera Stock analysis
When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| CEOs Directory Screen CEOs from public companies around the world |